An Investigation of Hormone and Lipid Associations after Weight Loss in Women

Objective: The objectives of this study were to determine 1) whether the extent of weight loss is predictive of the degree of changes in hormone and lipid levels; 2) the interactions between energy regulating hormones after weight loss through an energy deficit/exercise protocol diet and exercise; 3) whether initial metabolic parameters are indicative of the extent of weight loss. Methods: Thirty-five hyperlipidemic females (BMI 28–39 kg/m2) 35–60 years old participated in a six month weight loss trial. Weight loss resulted from a diet and exercise program that when combined produced a 30% energy deficit. Fasting plasma taken during 2 wk stabilization periods at the beginning and end of the study was analysed for lipids, hormone and glucose levels. Results: Average weight loss was 11.7 ± 2.5 kg (p < 0.0001). TC, LDL-C, and triacylglycerols decreased 9.3 ± 9.5% (p < 0.0001), 7.4 ± 12.2% (p < 0.001), and 26.8 ± 19.6% (p < 0.05), respectively, while HDL-C increased (p < 0.05) by 8.2 ± 16.3%. Leptin levels declined (p < 0.001) 48.9 ± 16.0% and ghrelin levels rose (p < 0.001) 21.2 ± 26.7%. While overall levels of adiponectin did not differ, individual values changed such that weight loss predicted increases in adiponectin levels. Though initial weight did not predict weight loss, baseline lipid and insulin levels positively predicted weight loss. Conclusion: Initial metabolic parameters may be predictors of weight loss. Beneficial effects of weight loss as achieved through diet and exercise on measured parameters indicate moderate weight loss reduces key risk factors of cardiovascular disease in overweight individuals.

[1]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[2]  B. Zahorska-Markiewicz,et al.  Effect of weight reduction on serum ghrelin and TNFalpha concentrations in obese women. , 2004, European journal of internal medicine.

[3]  C. Ballantyne,et al.  Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. , 2004, The Journal of clinical endocrinology and metabolism.

[4]  R. Vigneri,et al.  Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. , 2004, The Journal of clinical endocrinology and metabolism.

[5]  G. Yoshino,et al.  Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. , 2004, Metabolism: clinical and experimental.

[6]  Cynthia J. Girman,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[7]  J. Kral,et al.  Ghrelin: Integrative Neuroendocrine Peptide in Health and Disease , 2004, Annals of surgery.

[8]  Arshag D Mooradian,et al.  Nutrition principles and recommendations in diabetes. , 2004, Diabetes care.

[9]  B. Nicklas,et al.  Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women , 2003, International Journal of Obesity.

[10]  Alessandro Pontillo,et al.  Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. , 2003, JAMA.

[11]  Pedro Iglesias,et al.  The role of the novel adipocyte-derived hormone adiponectin in human disease. , 2003, European journal of endocrinology.

[12]  H. Boeing,et al.  Adiponectin and protection against type 2 diabetes mellitus , 2003, The Lancet.

[13]  R. Marfella,et al.  Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women , 2003 .

[14]  M. Matsuda,et al.  Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.

[15]  K. Kangawa,et al.  Weight loss increases circulating levels of ghrelin in human obesity , 2002, Clinical endocrinology.

[16]  T. McLaughlin,et al.  Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. , 2001, Metabolism: clinical and experimental.

[17]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[18]  T. Y. Wang,et al.  Low triglyceride levels affect calculation of low-density lipoprotein cholesterol values. , 2001, Archives of pathology & laboratory medicine.

[19]  M. Raeini-Sarjaz,et al.  Comparison of the effect of dietary fat restriction with that of energy restriction on human lipid metabolism. , 2001, The American journal of clinical nutrition.

[20]  S. Toubro,et al.  Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial , 2001, International Journal of Obesity.

[21]  H. Gylling,et al.  Cholesterol absorption efficiency and sterol metabolism in obesity. , 2000, Atherosclerosis.

[22]  J W Erdman,et al.  AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. , 2000, Circulation.

[23]  L. Katzel,et al.  Weight loss due to energy restriction suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. , 1999, The Journal of nutrition.

[24]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[25]  N. Rifai,et al.  Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method. , 1998, Clinical chemistry.

[26]  S. Klein,et al.  Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. , 1996, The Journal of clinical endocrinology and metabolism.

[27]  P. Wilson,et al.  Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. , 1996, Clinical chemistry.

[28]  E. Ravussin,et al.  Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.

[29]  R. Hamman,et al.  High fasting insulin levels associated with lower rates of weight gain in persons with normal glucose tolerance: the San Luis Valley Diabetes Study. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[30]  R. Wing,et al.  Effect of modest weight loss on changes in cardiovascular risk factors: are there differences between men and women or between weight loss and maintenance? , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[31]  J. Dietschy,et al.  Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. , 1993, Journal of lipid research.

[32]  C. Christiansen,et al.  Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. , 1993, The American journal of medicine.

[33]  A. Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[34]  E. Ravussin,et al.  Insulin resistance associated with lower rates of weight gain in Pima Indians. , 1991, The Journal of clinical investigation.

[35]  E. Schaefer,et al.  Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[36]  A. Lazarow,et al.  Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats , 1963, Diabetes.